HBM Holdings Limited

HBM Holdings Limited is a biopharmaceutical company in the clinical development phase, dedicated to the discovery and advancement of differentiated antibody therapeutics for immunological and oncological disorders. The firm's robust pipeline includes several notable candidates: Batoclimab (HBM9161), a human monoclonal antibody designed to selectively bind to and inhibit the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036), intended to address moderate to severe dry eye disease; HBM7008, a bispecific antibody engineered to engage tumor-associated antigens; and HBM4003, a human anti-CTLA-4 antibody directed against cytotoxic T-lymphocyte-associated antigen-4. Furthermore, HBM is advancing HBM9022 as a treatment for SARS-COV-2, HBM9302 for breast and gastric cancers, and HBM7020 for multiple myeloma. A diverse array of other compounds, such as HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022, are also under development for various solid tumors. HBM Holdings maintains a global operational footprint, spanning Mainland China, the United States, Europe, and other international territories. The company has established strategic partnerships for antibody-drug conjugate (ADC) initiatives with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. Incorporated in 2016, HBM Holdings Limited's corporate headquarters are located in Shanghai, People's Republic of China.